Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapid Exchange In Cardiac Cath Space: Medtronic Launches, Abbott Sues

This article was originally published in The Gray Sheet

Executive Summary

Medtronic finally reentered the U.S. market with popular rapid-exchange (RX) coronary catheter delivery systems Oct. 30 after an eight-year absence, prompting an immediate patent infringement suit from Abbott
Advertisement

Related Content

Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.
Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.
Patent Face-Off: FDA Denial Isn’t The End Of Rapid-Exchange Dispute
Patent Face-Off: FDA Denial Isn’t The End Of Rapid-Exchange Dispute
Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
Medtronic, AngioScore Challenge Abbott’s Attempt To Extend Catheter Patent
Medtronic, AngioScore Challenge Abbott’s Attempt To Extend Catheter Patent
Advertisement
UsernamePublicRestriction

Register

MT026750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel